Molecular docking and structure-based drug design strategies LG Ferreira, RN Dos Santos, G Oliva, AD Andricopulo Molecules 20 (7), 13384-13421, 2015 | 2393 | 2015 |
ADMET modeling approaches in drug discovery LLG Ferreira, AD Andricopulo Drug discovery today 24 (5), 1157-1165, 2019 | 613 | 2019 |
Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective LG Ferreira, AD Andricopulo Drug Discovery Today 21 (10), 1699-1710, 2016 | 106 | 2016 |
Medicamentos e tratamentos para a Covid-19 LLG Ferreira, AD Andricopulo Estudos avançados 34 (100), 7-27, 2020 | 96 | 2020 |
Targeting cysteine proteases in trypanosomatid disease drug discovery LG Ferreira, AD Andricopulo Pharmacology & therapeutics 180, 49-61, 2017 | 88 | 2017 |
Approaches to advance drug discovery for neglected tropical diseases LLG Ferreira, J de Moraes, AD Andricopulo Drug Discovery Today 27 (8), 2278-2287, 2022 | 78 | 2022 |
Recent advances and perspectives in cancer drug design LG Magalhaes, LLG Ferreira, AD Andricopulo Anais da Academia Brasileira de Ciências 90 (1 Suppl 2), 1233-1250, 2018 | 69 | 2018 |
Practices in molecular docking and structure-based virtual screening RN Dos Santos, LG Ferreira, AD Andricopulo Computational drug discovery and design, 31-50, 2018 | 66 | 2018 |
Phenotypic screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the treatment of schistosomiasis EM Lago, MP Silva, TG Queiroz, SF Mazloum, VC Rodrigues, ... EBioMedicine 43, 370-379, 2019 | 62 | 2019 |
Antifungal compounds from Streptomyces associated with attine ants also inhibit Leishmania donovani HE Ortega, LLG Ferreira, WGP Melo, ALL Oliveira, RF Ramos Alvarenga, ... PLOS Neglected Tropical Diseases 13 (8), e0007643, 2019 | 59 | 2019 |
Discovery of Novel Antischistosomal Agents by Molecular Modeling Approaches AC Mafud, LG Ferreira, YP Mascarenhas, AD Andricopulo, J De Moraes Trends in Parasitology 32 (11), 874-886, 2016 | 56 | 2016 |
Meliponamycins: Antimicrobials from Stingless Bee-Associated Streptomyces sp. C Menegatti, VB Lourenzon, D Rodriguez-Hernandez, ... Journal of natural products 83 (3), 610-616, 2020 | 55 | 2020 |
Drugs and vaccines in the 21st century for neglected diseases LLG Ferreira, AD Andricopulo The Lancet Infectious Diseases 19 (2), 125-127, 2019 | 49 | 2019 |
Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach ML de Souza, C de Oliveira Rezende Junior, RS Ferreira, ... Journal of chemical information and modeling, 2020 | 48 | 2020 |
H1-antihistamines as antischistosomal drugs: in vitro and in vivo studies RP Xavier, AC Mengarda, MP Silva, DB Roquini, MC Salvadori, ... Parasites & Vectors 13, 1-12, 2020 | 37 | 2020 |
Target-based molecular modeling strategies for schistosomiasis drug discovery LG Ferreira, G Oliva, AD Andricopulo Future Medicinal Chemistry 7 (6), 753-764, 2015 | 36 | 2015 |
Structure-Based and Molecular Modeling Studies for the Discovery of Cyclic Imides as Reversible Cruzain Inhibitors With Potent Anti-Trypanosoma cruzi Activity RAA Ferreira, I Pauli, TS Sampaio, ML de Souza, LLG Ferreira, ... Frontiers in chemistry 7, 798, 2019 | 29 | 2019 |
From medicinal chemistry to human health: current approaches to drug discovery for cancer and neglected tropical diseases LG Ferreira, G Oliva, AD Andricopulo Anais da Academia Brasileira de Ciências 90, 645-661, 2018 | 29 | 2018 |
Molecular modeling and structure–activity relationships for a series of benzimidazole derivatives as cruzain inhibitors I Pauli, LG Ferreira, ML de Souza, G Oliva, RS Ferreira, MA Dessoy, ... Future medicinal chemistry 9 (7), 641-657, 2017 | 28 | 2017 |
Protein-protein interaction inhibitors: advances in anticancer drug design LG Ferreira, G Oliva, AD Andricopulo Expert Opinion on Drug Discovery 11 (10), 957-968, 2016 | 28 | 2016 |